Cephalon, Inc.
http://www.cephalon.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cephalon, Inc.
Chinese Language Podcast: ASCO专集
J&J and Legend’s Carvykti shines at ASCO while Junshi provides PD-1 antibody toripalimab updates. Alongside, ADCs from Biokin, BlissBio also steps into the spotlight. Guest speaker Leon Tang in the US, Brian Yang in Beijing and Dexter Yan in Shanghai discuss what stands out in this special ASCO episode of the latest Chinese-language podcast.
Asia Deal Watch: Busy Eikon Partners With Impact On Selective PARP1 Inhibitors
Yuhan and J INTS BIO and Betta and C4 sign deals centered on lung cancer candidates. Viatris’s Japanese affiliate gets in-country rights to InDex’s Phase III ulcerative colitis candidate.
Dr Reddy’s CEO: We’re In ‘Great Dialogue’ With The Innovation Industry In China
Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Company Information
- Other Names / Subsidiaries
-
- Arana Therapeutics (Peptech and EvoGenix)
- BioAssets Development Corporation
- Ception Therapeutics
- ChemGenex Pharmaceuticals Limited
- CIMA Labs
- Gemin X Pharmaceuticals
- Zeneus Pharma
- Mepha
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice